PCN52 ABIRATERONE VERSUS ENZALUTAMIDE IN THE POST-CHEMOTHERAPY SETTING IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: POPULATION-BASED STUDY
Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.249
https://www.valueinhealthjournal.com/article/S1098-3015(19)32627-0/fulltext
Title :
PCN52 ABIRATERONE VERSUS ENZALUTAMIDE IN THE POST-CHEMOTHERAPY SETTING IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: POPULATION-BASED STUDY
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)32627-0&doi=10.1016/j.jval.2019.09.249
First page :
Section Title :
Open access? :
No
Section Order :
10197